XBiotech Inc.
NASDAQ:XBIT · NASDAQ Global Select
+$0.01 today
Vol 0.01M · Avg 0.03M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:XBIT · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$40.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.32, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 -100.0% | $4.0M -78.2% | $18.4M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $1.7M | $0 | $0 -100.0% | $651.0K -88.8% | $5.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$1.7M | $0 | $0 -100.0% | $3.4M -73.3% | $12.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | 83.8% +15.4pp | 68.4% | 9.8% | 28.9% | 38.3% |
| Research & Development | $47.4M +25.5% | $37.8M +14.9% | $32.8M +4.1% | $31.5M +11.6% | $28.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $8.3M +76.0% | $4.7M +1.1% | $4.7M -26.1% | $6.3M -32.8% | $9.4M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $54.0M +27.1% | $42.5M +13.2% | $37.5M -0.9% | $37.8M +0.5% | $37.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $1.7M -3.4% | $1.7M +0.1% | $1.7M -33.3% | $2.6M -1.3% | $2.6M | $374.2M | $1.2B | $631.8M |
| EBITDA | -$43.5M -20.9% | -$36.0M -59.6% | -$22.6M +27.1% | -$31.0M -35.8% | -$22.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | -772.4% -648.4pp | -124.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$55.7M -31.1% | -$42.5M -13.2% | -$37.5M -8.8% | -$34.5M -37.5% | -$25.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | -860.1% -723.7pp | -136.4% | 16.6% | 24.1% | 22.0% |
| Interest Income | $5.7M -42.1% | $9.8M -5.8% | $10.4M +172.6% | $3.8M +718.6% | $467.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $88.0K -89.1% | $807.0K | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $10.4M +165.6% | $3.9M -70.4% | $13.2M +1363.1% | $902.0K +339.9% | -$376.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$45.3M -17.5% | -$38.6M -58.6% | -$24.3M +27.6% | -$33.6M -31.9% | -$25.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | -837.6% -699.2pp | -138.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $235.0K +834.4% | -$32.0K -113.1% | $244.0K +135.5% | -$688.0K +91.4% | -$8.0M | $1.3B | -$1.6B | $745.2M |
| Net Income | -$45.5M -18.2% | -$38.5M -56.9% | -$24.6M +25.4% | -$32.9M -88.9% | -$17.4M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | -820.4% -725.8pp | -94.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -18.3% | -$1 -55.6% | -$1 +25.0% | -$1 -86.2% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -18.3% | -$1 -55.6% | -$1 +25.0% | -$1 -86.2% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $30.5M +0.1% | $30.5M +0.5% | $30.3M -0.4% | $30.4M +1.3% | $30.0M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $30.5M +0.1% | $30.5M +0.1% | $30.4M -0.0% | $30.4M +1.3% | $30.0M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Relmada Therapeutics, Inc.
NASDAQ:RLMD
$487.67M
Adagene Inc.
NASDAQ:ADAG
$134.41M
Fortress Biotech, Inc.
NASDAQ:FBIO
$92.02M
Adicet Bio, Inc.
NASDAQ:ACET
$75.25M
Gain Therapeutics, Inc.
NASDAQ:GANX
$71.66M
TScan Therapeutics, Inc.
NASDAQ:TCRX
$55.71M
Acrivon Therapeutics, Inc. Common Stock
ACRV
$46.70M
Nutriband Inc.
NTRB
$41.21M
Lite Strategy, Inc.
LITS
$25.22M
CervoMed Inc.
CRVO
$22.68M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does XBIT generate?
XBiotech Inc. (XBIT) reported $0.00 of revenue in fiscal 2025.
Is XBIT profitable?
XBiotech Inc. (XBIT) reported -$45,540,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.